2012年8月11日 訊 /生物谷BIOON/ --一項(xiàng)大型的觀察性研究發(fā)現(xiàn)了日常阿司匹林?jǐn)z入和低癌癥死亡率相關(guān)的大量證據(jù)，相關(guān)研究報(bào)告刊登在了近日的國(guó)際雜志the Journal of the National Cancer Institute（JNCI）上,，為日常阿司匹林使用于低癌癥死亡率提供了支持,。
文章中，研究者表示,，使用阿司匹林5年及以上的人群,，其癌癥死亡率的風(fēng)險(xiǎn)可降低37%。但是又有很多問(wèn)題存在,，比如說(shuō),，每天服用多少阿司匹林才能降低癌癥死亡率等等。
研究者Eric分析了100,，139位癌癥老年患者的信息,，發(fā)現(xiàn)每日服用阿司匹林可使其癌癥死亡風(fēng)險(xiǎn)降低16%，研究中的癌癥死亡風(fēng)險(xiǎn)降低率（16%）相比大量隨機(jī)比對(duì)試驗(yàn)的死亡降低率（37%）明顯小了,，研究者表示,，他們的研究是觀察檢測(cè)得到的，而并非是隨機(jī)試驗(yàn)而來(lái),。
制定臨床指導(dǎo)方針的專家委員會(huì)會(huì)考慮阿司匹林的風(fēng)險(xiǎn)和益處來(lái)制定最終的策略,，當(dāng)然盡管阿司匹林?jǐn)z入和低癌癥死亡率的結(jié)果鼓舞人心，但是也不能盲目告訴人們開始服用阿司匹林來(lái)抑制癌癥發(fā)生,。甚至低劑量的阿司匹林還會(huì)增加嚴(yán)重的胃腸道出血的風(fēng)險(xiǎn)。服用阿司匹林最好還是在專家的指導(dǎo)下來(lái)進(jìn)行,。（生物谷Bioon.com）
編譯自：Daily Aspirin Usage Linked to Lower Cancer Mortality
doi:10.1093/jnci/djs318
PMC:
PMID:
Daily Aspirin Use and Cancer Mortality in a Large US Cohort
Eric J. Jacobs, Christina C. Newton, Susan M. Gapstur and Michael J. Thun
Background A recent pooled analysis of randomized trials of daily aspirin for prevention of vascular events found a substantial reduction (relative risk [RR] = 0.63, 95% confidence interval [CI] = 0.49 to 0.82) in overall cancer mortality during follow-up occurring after 5 years on aspirin. However, the magnitude of the effect of daily aspirin use, particularly long-term use, on cancer mortality is uncertain. Methods We examined the association between daily aspirin use and overall cancer mortality among 100 139 men and women with no history of cancer in the Cancer Prevention Study II Nutrition Cohort. Cox proportional hazards regression models were used to estimate multivariable-adjusted relative risks (RRs) and 95% confidence intervals (CIs). Results Between 1997 and 2008, 5138 participants died from cancer. Compared with no use, daily aspirin use at baseline was associated with slightly lower cancer mortality, regardless of duration of daily use (for <5 years of use, RR = 0.92, 95% CI = 0.85 to 1.01; for ≥5 years of use, RR = 0.92, 95% CI = 0.83 to 1.02). Associations were slightly stronger in analyses that used updated aspirin information from periodic follow-up questionnaires and included 3373 cancer deaths (for <5 years of use, RR = 0.84, 95% CI = 0.76 to 0.94; for ≥5 years of use, RR = 0.84, 95% CI = 0.75 to 0.95). Conclusion These results are consistent with an association between recent daily aspirin use and modestly lower cancer mortality but suggest that any reduction in cancer mortality may be smaller than that observed with long-term aspirin use in the pooled trial analysis.
